SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-011984 to Alpha Teknova, Inc. (TKNO)

Alpha Teknova, Inc.
Date: Nov. 2, 2023 · CIK: 0001850902 · Accession: 0000000000-23-011984

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-275168

Date
November 2, 2023
Author
Cindy Polynice
Form
UPLOAD
Company
Alpha Teknova, Inc.

Letter

United States securities and exchange commission logo November 2, 2023 Stephen Gunstream President and Chief Executive Officer Alpha Teknova, Inc. 2451 Bert Dr. Hollister, CA 95023 Re:Alpha Teknova, Inc. Registration Statement on Form S-1 Filed October 25, 2023 File No. 333-275168 Dear Stephen Gunstream: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Elizabeth Razzano, Esq.

Show Raw Text
United States securities and exchange commission logo
November 2, 2023
Stephen Gunstream
President and Chief Executive Officer
Alpha Teknova, Inc.
2451 Bert Dr.
Hollister, CA 95023
Re:Alpha Teknova, Inc.
Registration Statement on Form S-1
Filed October 25, 2023
File No. 333-275168
Dear Stephen Gunstream:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Elizabeth Razzano, Esq.